TCRX Q4 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$24M

Net Income

-$23M

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$229M

Total Liabilities

$106M

Stockholders' Equity

$123M

Cash & Equivalents

$152M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$665,000	-100.0%
Gross Profit	$0	$665,000	-100.0%
Operating Income	-$24M	-$37M	+35.0%
Net Income	-$23M	-$36M	+35.8%

Revenue Segments

Reportable Segment

$3M100%